Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
JP Westwood(University College London), Marie Scully(University College London Hospitals NHS Foundation Trust), Siobhan McGuckin(University College Hospital), Samuel J. Machin(University College London), Henry Goodwin Webster(University College London), Vickie McDonald(University College London)
Cited by 175
Related Papers
The “Primary” Antiphospholipid Syndrome
|Medicine|1989|963
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
|Blood|2011|420